One thing's now for sure--those divestitures include Salix, the GI drugmaker whose 2015 purchase created much of the company's current debt burden. And as the WSJ reported Tuesday, Valeant may have a willing buyer in Takeda, which is reportedly weighing a $10 billion deal that includes $8.5 billion in cash. That cash could come in handy more than ever, thanks to a federal accounting fraud probe into Valeant's former relationship with now-dead specialty pharmacy Philidor.